GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04652076 |
|
Recruitment Status :
Recruiting
First Posted : December 3, 2020
Last Update Posted : March 17, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Endometrial Carcinoma Cervix Carcinoma | Drug: NP137 Drug: Pembrolizumab Drug: Paclitaxel Drug: Carboplatin | Phase 1 Phase 2 |
The prognosis of patients with locally advanced/metastatic uterine (endometrial or cervical) cancer progressing/relapsing after at least one prior systemic treatment remains poor. The development of new innovative anti-tumor drug candidates as single agent or in combination with chemotherapy or check point inhibitors is needed.
NP137 is a first-in-class humanized monoclonal antibody targeting specifically and selectively Netrin-1. By blocking Netrin-1, NP137 is capable of restoring apoptosis in tumor cells in vitro and in vivo, leading to therapeutic activity in various animal cancer models.
Dependence receptors inhibitor such as NP137 might be a novel choice to improve the clinical outcomes of these patients.
The herein proposed study will be a multicenter, open-label, randomized, Phase I/II trial with:
A safety run in part to assess the safety of the therapeutic combinations for the first 6 patients enrolled in each of the therapeutic combinations independently of the tumor type. According to safety rules, these therapeutic combinations will be investigated or not in the Phase II part.
A Phase II part will be then conducted using an adaptive Bayesian approach allowing to quickly stop treatment cohorts without evidence of efficacy and/or select promising treatment cohorts. The Phase II part will be initiated with a preliminary step to assess the clinical activity of the proposed therapeutic combinations in 2 tumor types before proceeding to the activation of extension phase II part of the study. For each cohorts, clinical activity will be assessed through by sequential statistical analysis at specific timepoints.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 240 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy. |
| Actual Study Start Date : | December 14, 2020 |
| Estimated Primary Completion Date : | October 25, 2023 |
| Estimated Study Completion Date : | November 25, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)
Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
|
Drug: Paclitaxel
Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment. Drug: Carboplatin Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment. |
|
Arm B: Experimental double combination [Standard Chemotherapy +NP137]
Experimental double combination [Standard Chemotherapy +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
|
Drug: NP137
Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first. Drug: Paclitaxel Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment. Drug: Carboplatin Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment. |
|
Arm C: Experimental double combination [Pembrolizumab +NP137]
Experimental double combination [Pembrolizumab +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
|
Drug: NP137
Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first. Drug: Pembrolizumab Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
Other Name: KEYTRUDA |
|
Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]
Experimental triple combination [Pembrolizumab+ Standard Chemotherapy + NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
|
Drug: NP137
Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first. Drug: Pembrolizumab Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
Other Name: KEYTRUDA Drug: Paclitaxel Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment. Drug: Carboplatin Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment. |
- DLT occurrence [ Time Frame: Safety run in Period: At the end of Cycle 2 (each cycle is 21 days) for the first 6 to 12 patients per arm ]Any pre-definied toxicities graded by using NCI CTCAE Version 5.0 and assessed by the investigator to be possibly, probably, or definitely related to study treatments administration during the safety run in period
- Overall response Rate (ORR) [ Time Frame: At 3 months of treatement and then every 12 weeks, up to 2 years ]Rate of patients with CR or PR as per RECIST 1.1
- Clinical Benefit Rate (CBR) [ Time Frame: Every 12 weeks, up to 2 years ]The proportion of evaluable patients with an objective response according to RECIST 1.1.
- Duration of Response [ Time Frame: Every 12 weeks, up to 2 years ]Time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression or death is documented,
- Progression-free Survival [ Time Frame: Every 12 weeks, up to 2 years ]Time from first study drug intake until disease progression or death, whichever occurs first
- Overall Survival [ Time Frame: Every 12 weeks, up to 2 years ]Time from the first day of study treatment to the date of death due to any cause.
- Best Overall Response [ Time Frame: Every 12 weeks, up to 2 years ]The best response designation between the date of the first study treatment and the date of objectively documented progression or the date of subsequent anti-cancer therapy
- Pharmacokinetic parameter: Cmax [ Time Frame: Over the first 6 cycles (each cycle is 21 days) of patients treated with NP137 and enrolled during the Safety run in period ]Plasma peak concentration
- Pharmacokinetic parameter: tmax [ Time Frame: Over the first 6 cycles (each cycle is 21 days) of patients treated with NP137 and enrolled during the Safety run in period ]Time to reach the peak concentration
- Pharmacokinetic parameter: AUCt [ Time Frame: Over the first 6 cycles (each cycle is 21 days) of patients treated with NP137 and enrolled during the Safety run in period ]Area under the concentration-time curve from time zero to the last sample with the quantifiable concentration
- Pharmacokinetic parameter: AUC∞ [ Time Frame: Over the first 6 cycles (each cycle is 21 days) of patients treated with NP137 and enrolled during the Safety run in period ]Area under the concentration-time curve from time zero to infinity corresponding to the definite integral of a curve that describes the variation of a drug concentration in blood plasma as a function of time (drug exposure in plasma)
- Pharmacokinetic parameter: CL [ Time Frame: Over the first 6 cycles (each cycle is 21 days) of patients treated with NP137 and enrolled during the Safety run in period ]Clearance: volume of plasma from which NP137 is completely removed per unit time.
- Pharmacokinetic parameter: t1/2 [ Time Frame: Over the first 6 cycles of the patients Treated with NP137 and enrolled during the Safety run in period ]Terminal elimination half-life: time required for the amount of NP137 in the body to decrease by half.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be women ≥ 18 years at time of inform consent signature.
- Patient with histologically confirmed locally advanced / metastatic endometrial carcinoma (Endometrial sarcoma are excluded) or patient with histologically confirmed locally advanced / metastatic cervix adeno- or epidermoid- carcinoma.
- Previously treated by at least one line of platinum based chemotherapy, but no more than 3 lines of chemotherapies whatever the nature. If the previous based platinum chemotherapy was given as neoadjuvant or adjuvant chemotherapy for a local disease (stage I or II), inclusion must be performed no more than one year after the end of this chemotherapy, except if an advanced or metastatic relapse has been documented and treated by a systemic anti-cancer agent during this time interval.
In all cases, a minimal wash-out period of 6 months after completion of last chemotherapy with [platinum + paclitaxel] is required prior to entering the study.
Platinum chemotherapy concomitant to RT can not be considered as a line of previous platinum based chemotherapy.
- For endometrium carcinoma: mutational profile (MSI/MSS status) available before randomization (see St Paul de Vence 2019- ARCAGY - GINECO Group recommendation).
- Documented disease progression as per RECIST V1.1 after prior systemic chemotherapy regimen and presence of at least one lesion evaluable for response according to RECIST 1.1.
- Have provided a representative archival tumor sample in formalin-fixed paraffin embedded (FFPE) block (primary tumor or metastasis) or newly obtained core or excisional biopsy of a tumor lesion together with an associated pathology report.
Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut (details pertaining to tumor tissue submission can be found in the laboratory manual).
- Optional for patients having consented to tumor biopsies: presence of at least one tumor lesion visible by medical imaging and accessible to repeatable percutaneous sampling that permits core needle biopsy without unacceptable risk of a significant procedural complications, and suitable for retrieval of 4 cores using a 16-gauge diameter needle or larger.
Note: lesions to be biopsied should not be selected as RECIST target lesions. Bone lesions are not adequate lesions for biopsies and lymph nodes lesions should not be considered as prime targets.
- Life expectancy ≥ 3 months.
- Eastern Cooperative Oncology GrougGroup performance status (ECOG PS) of 0 to 1.
-
Demonstrate adequate cardiovascular function:
- QTcF < 470ms
- Resting BP systolic <160mmHg and diastolic < 100mmHg
- LVEF > 50% as determined by transthoracic echocardiogram.
- Demonstrate adequate organ function as defined in protocol, all screening laboratory tests should be performed within 7 days prior C1D1:
- Women of child-bearing potential must have a negative urine pregnancy test at screening (within 72 hours prior C1D1) and must agree to use 2 effective forms of contraception from the time of the treatment period and of the negative pregnancy test up 6 months after the end of their treatment.
- Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures.
- Patient should be able and willing to comply with study visits and procedures as per protocol.
Exclusion Criteria:
- Patients with progression during previous chemotherapy with [platinum +paclitaxel]
- Persistence of CTCAE ≥ Grade 2 toxicity due to prior anti-cancer therapy (except alopecia (any grades).
- History of severe (≥Grade 3) allergic anaphylactic reactions to one of the components of NP137, pembrolizumab, paclitaxel, carboplatin and/or any of their excipients.
- Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
-
Prior/concomitant Therapy:
- Have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade ≥ 3 irAE
- Have received prior systemic anti-cancer therapy :
- Chemotherapy or targeted therapies (approved or investigational) within 2 weeks or 5* t1/2 whichever is longer prior C1D1.
- Hormonal therapy within 1 week prior to C1D1
-
Biological therapy within 4 weeks prior to C1D1
- Are currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent. Have received prior radiotherapy within 4 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.
- Have had major surgery within 4 weeks of start of study treatment. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment, C1D1.
- Have received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Note: killed vaccinesare allowed.
- Have received immunosuppressive medication within 2 weeks with the exceptions of intranasal, topical and inhaled corticosteroids or systemic corticosteroids at doses which are not to exceed 10 mg/day of prednisone, or equivalent doses of another corticosteroid.
-
Have a history of autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. History of autoimmune disease which include but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis with the following exceptions:
- Patients with a history of autoimmune-related hypothyroidism who are on stable thyroid replacement hormone therapy,
- Patients with controlled Type 1 diabetes mellitus,
-
patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are eligible provided that they meet the following conditions:
- Rash must cover less than 10% of body surface area (BSA).
- Disease is well controlled at baseline and only requiring low potency topical steroids.
- No acute exacerbations of underlying condition within the previous 12 months requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoid, biologic agents, oral calcineurin inhibitors, high potency or oral steroids.
- Patients with HIV, active B or C hepatitis infection. Notes: Active hepatitis B i.e. chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening before C1D1. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to C1D1. Patients with a positive HBcAb test must have a negative HBV DNA test at screening. Active hepatitis C i.e. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA at screening.
- Patients with active tuberculosis.
- Prior allogeneic bone marrow transplantation or solid organ transplant for another malignancy in the past.
- History of idiopathic pulmonary fibrosis, non-infectious pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease , drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan.
- Have an active infection requiring systemic therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04652076
| Contact: Ray-Coquard Isabelle, MD, PhD | +33(0)4 78 78 28 28 | isabelle.ray-coquard@lyon.unicancer.fr |
| France | |
| CHRU BESANCON - Hopital Jean Minjoz | Recruiting |
| Besançon, France | |
| Contact: Elsa KALBACHER, MD 03 81 66 93 82 ekalbacher@chu-besancon.fr | |
| Institut Bergonié | Recruiting |
| Bordeaux, France | |
| Contact: Coriolan LEBRETON, MD c.lebreton@bordeaux.unicancer.fr | |
| Centre François Baclesse | Recruiting |
| Caen, France | |
| Contact: Florence JOLY, MD f.joly@baclesse.unicancer.fr | |
| Centre Georges François Leclerc | Recruiting |
| Dijon, France | |
| Contact: Jean-David FUMET, MD 0380737506 jdfumet@cgfl.fr | |
| Primary Completion Date | Recruiting |
| Lille, France | |
| Contact: Cyril ABDEDDAIM, MD c-abdeddaim@o-lambret.fr | |
| Centre Léon Bérard | Recruiting |
| Lyon, France | |
| Contact: Isabelle RAY COQUARD, MD,PhD 04 78 78 28 88 isabelle.ray-coquard@lyon.unicancer.fr | |
| Primary Completion Date | Recruiting |
| Marseille, France | |
| Contact: Magali PROVANSAL, MD Primary Completion Date provansalm@ipc.unicancer.fr | |
| ICM - Val d'Aurelle | Recruiting |
| Montpellier, France | |
| Contact: Michel FABBRO, MD 04 67 61 30 63 michel.fabbro@icm.unicancer.fr | |
| Insitut de cancérologie de l'ouest | Recruiting |
| Nantes, France | |
| Contact: Jean-Sébastien FRENEL, MD jean-sebastien.frenel@ico.unicancer.fr | |
| Hopital de la Croix Saint Simon | Recruiting |
| Paris, France, 75020 | |
| Contact: Frederic SELLE, MD FSelle@hopital-dcss.org | |
| Institut Curie (Site Saint Cloud) | Recruiting |
| Paris, France, 92210 | |
| Contact: Alexandre DE MOURA, MD alexandre.demoura@curie.fr | |
| Institut Gustave Roussy | Recruiting |
| Paris, France, 94800 | |
| Contact: Alexandra LEARY, MD alexandra.leary@gustaveroussy.fr | |
| Aphp Cochin | Recruiting |
| Paris, France | |
| Contact: Jerome ALEXANDRE, MD, PhD 01 58 41 14 39 jerome.alexandre@aphp.fr | |
| Centre Eugène Marquis | Recruiting |
| Rennes, France | |
| Contact: Thibault DE LA MOTTE ROUGE, MD 02 99 25 31 71 t.delamotterouge@rennes.unicancer.fr | |
| Institut claudius Regaud | Recruiting |
| Toulouse, France | |
| Contact: Laurence GLADIEFF, MD 05 31 15 51 01 gladieff.laurence@iuct-oncopole.fr | |
| Responsible Party: | NETRIS Pharma |
| ClinicalTrials.gov Identifier: | NCT04652076 |
| Other Study ID Numbers: |
NP137CT02 2020-000172-38 ( EudraCT Number ) /ET20-049 ( Other Identifier: Centre Léon Berard protocol number ) ANR-18-RHUS-0009 ( Other Grant/Funding Number: Agence Nationale de Recherche ) KEYNOTE-A92 ( Other Identifier: Merck Sharp & Dohme Corp. protocol number ) |
| First Posted: | December 3, 2020 Key Record Dates |
| Last Update Posted: | March 17, 2023 |
| Last Verified: | August 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
anti-Netrin 1 anti-PD-1 Immunotherapy Check Point Inhibitors Dependence Receptors |
|
Carcinoma Endometrial Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Uterine Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Genital Diseases Paclitaxel Carboplatin Pembrolizumab Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors |